🔴 Tiziana Life Sciences is trading 10% down on October 12, 2026 — without clear company-specific catalyst

Tiziana Life Sciences is trading at $1.07, down 10.08%, with no clear company-specific catalyst identified for the October 12 decline.

• The latest company announcement found was its September 30 FDA orphan-drug designation filing for intranasal foralumab.
• The market snapshot shows mixed major indexes, none down more than 0.5%, and does not establish a broad-market explanation for the drop.
• The September filing is prior news and does not by itself explain the current decline.